Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics

BACKGROUND AND AIM: Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti‐PD1/P...

Descripción completa

Detalles Bibliográficos
Autores principales: Mou, Haibo, Yang, Qiu‐an, Yu, Lanfang, Wang, Ting, Liu, Kui, Shen, Rong, Pan, Xuedong, Dai, Yi, Wan, Qing, Zhou, Fangling, Qian, Lili, Chen, Donglin, Yau, Thomas, Dong, Xiaowei, Wang, Xuemei, Wang, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Experimental Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518358/
https://www.ncbi.nlm.nih.gov/pubmed/33656759
http://dx.doi.org/10.1111/jgh.15475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518358/
https://www.ncbi.nlm.nih.gov/pubmed/33656759
http://dx.doi.org/10.1111/jgh.15475

Ejemplares similares